1 new0 added1 reduced44 sold outnet sold ≈ $97.4m (-21.0m shares)
* Summed across managers. Shares that two managers' reports both contain – a
subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are
counted once.
Holder counts are more reliable.
Implied quarter-end price ≈ $4.63.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
Quarter
Holders
Q3 2022
52
Q4 2022
49
Q1 2023
46
Q2 2023
2
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D
if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the
stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder
worked them out.
Holder
Stake
Change
Shares
Last filed
Hanmi Pharmaceutical Co., Ltd.
13D · may seek influencefiled 2025-03-20Stated purposeItem 4 of the Amended Statement is hereby amended to add the following at the end thereof:
The Reporting Person previously loaned certain amounts to the Issuer pursuant to and upon the terms and subject to the conditions set forth in that certain Facility Agreement, dated as of August 27, 2024, by and between the Reporting Person and the Issuer (the "Facility Agreement"), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On March 18, 2025, the Reporting Person and the Issuer entered into each of (i) that certain Debt Conversion and Interest Payment Agreement, dated as of March 18, 2025, by and between the Issuer and the Reporting Person (the "Conversion Agreement"), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herei…
Full filing